Be Sure . . . Use RAD-SURE™

blood irradiation indicators



ASHLAND®

With good chemistry great things happen.™

RAD-SURE™ blood irradiation indicators

Indicators for positive visual identification of irradiation

Transfusion-associated graft-versus-host disease (TA-GVHD), a rare complication of blood transfusion, is usually fatal. Patients in certain clinical categories, including bone marrow transplants, solid tumors and acquired T cell defects, are at greater risk of developing TA-GVHD. TA-GVHD can be prevented by the irradiation of cellular blood products prior to transfusion.

Ashland developed RAD-SURE blood irradiation indicators to provide positive, visual verification of irradiation. When attached to blood products, RAD-SURE Type XR 15 Gy, Type XR 25 Gy, Type 15 Gy and Type 25 Gy blood irradiation indicators show whether the blood products have been irradiated or not. Before a blood product and its attached indicator are irradiated, the indicator reads, "NOT IRRADIATED."

After the blood product and its attached indicator are irradiated, the word "NOT" in the indicator window is obscured and the indicator reads, "IRRADIATED." RAD-SURE blood irradiation indicators only indicate that irradiation has occurred. They should not be used as dosimeters to measure the dose delivered by the irradiator.

RAD-SURE Type 15 Gy and Type 25 Gy blood irradiation indicators should only be used with irradiators having cesium-137 or cobalt-60 radiation sources, or other sources producing radiation of equal or greater energy. RAD-SURE Type XR 15 Gy and Type XR 25 Gy blood irradiation indicators should only be used with x-ray irradiators that utilize x-rays generated from 160kVp sources that are filtered through 0.38 mm of copper, or 150kVp sources that are filtered through 1 mm of aluminum.


RAD-SURE blood irradiation indicators are FDA registered medical devices and CE marked

Registration/Listing Numbers:

FDA	BK910018	Type 15 Gy blood irradiation indicators
FDA	BK910018/1	Type XR 15 blood irradiation indicators
FDA	BK920035	Type 25 Gy blood irradiation indicators
FDA	A976736	Type XR 25 Gy blood irradiation indicators

CE marked

Examples of RAD-SURE Type XR 25 Gy and Type 25 Gy blood irradiation indicators before and after irradiation




Before irradiation


After irradiation


In addition to the above, French, Japanese and Polish versions of RAD-SURE are available.

RAD-SURE™ blood irradiation indicators – Stability

While RAD-SURE indicators should not be used after their stated expiration date and should be handled according to the Use Instructions, we have built a large margin of safety into the performance of the product. The stability of every batch of radiation-sensitive film is monitored at least until the shelf-life of the indicators expires. The results predict that indicators should remain stable long after their shelf life expires.








Exhibits I & II: Measurements of the stability of the radiation-sensitive film in RAD-SURE indicators stored at, or below, room temperature predict that the film should remain transparent for many years.

Exhibit III: While the Use Instructions state that prolonged exposure of RAD-SURE indicators to light should be avoided, test data shows that the radiation-sensitive film should remain transparent even after six months of continuous exposure to room light.



Global Headquarters

Ashland Inc.
50 East RiverCenter Blvd.
Covington, KY 41012 USA
Tel: +1 859 815 3333

Ashland Specialty Ingredients
8145 Blazer Drive
Wilmington, DE 19808 USA
Tel: +1 800 345 0447
Fax: +1 302 992 7287

Regional Sales Offices
North America
Roseland, NJ USA
Tel: +1 800 622 4423
Fax: +1 859 357 3763

ashland.com

® Registered trademark, Ashland or its subsidiaries, registered in various countries
™ Trademark, Ashland or its subsidiaries, registered in various countries
* Trademark owned by a third party
© 2013, 2014, Ashland
PC-12510.2

All statements, information and data presented herein are believed to be accurate and reliable, but are not to be taken as a guarantee, an express warranty, or an implied warranty of merchantability or fitness for a particular purpose, or representation, express or implied, for which Ashland Inc. and its subsidiaries assume legal responsibility.

ASHLAND

Features of RAD-SURE™ indicators

- Simple to use
- Easy to interpret
- Attaches easily to units of blood
- Contains radiation-sensitive film

Benefits of RAD-SURE indicators

- Reduces operator errors
- Provides positive, visual verification of irradiation
- Enhances quality assurance of blood irradiation
- Meets cGMP requirements

RAD-SURE blood irradiation indicators ordering information

Version	Product Code	Packaging
RAD-SURE 15 Gy blood irradiation indicators	831377	200/Box
RAD-SURE 25 Gy blood irradiation indicators	831379	200/Box
RAD-SURE XR 15 Gy blood irradiation indicators	831396	200/Box
RAD-SURE XR 25 Gy blood irradiation indicators	831398	200/Box

References

1. Anderson KC, Goodnough Lt., Sayers M., et al., "Variation in Blood Component Irradiation Practice: Implications for Prevention of TA-GVHD," Blood 1991:77:2096-102.
2. Leitman SF, "Dose, Dosimetry and Quality Improvement of Irradiated Blood Components," Transfusion 1993: 33:447-9.
3. Rosen NR, Weldner JG, Boldt HD, Rosen DS, "Prevention of TA-GVHD: Selection of an Adequate Dose of Gamma Radiation," Transfusion 1993: 33:125-7.
4. Blood Irradiation: A User's Guide, AABB Press 1996.
5. TLD Dosimetry Services Brochure, Landauer Inc., Glenwood, IL 1992.
6. DOSE-MAP® Dosimetry System Brochure, International Specialty Products, Wayne, NJ 2003.
7. Leitman SF, Silberstein L, Fairman RM, Lewis DF, "Use of a Radiation Sensitive Film Label in the Quality Control of Irradiated Blood Components," (Abstract), Transfusion 1992:32-8S.
8. Masterson ME, Febo R, "Pretransfusion Blood Irradiation: Clinical Rational and Dosimetric Considerations," Medical Physics 1992: 19:649-57.
9. Luban NLC, "Prevention of Transfusion-Associated Graft-Versus-Host Disease by Inactivation of T Cells in Platelet Components," Seminars in Hematology 2001: 38:4-11.
10. Moroff G, Luban NLC, "The Irradiation of Blood and Blood Components to Prevent Graft-Versus Host Disease: Technical Issues and Guidelines," Transfusion Medicine Reviews 1997:11-1.
11. FDA, "Guidance for Industry Gamma Irradiation of Blood and Blood Components: A Pilot Program for Licensing," 2000.
12. Moroff G, Leitman SF, Luban NLC, "Principles of Blood Irradiation, Dose Validation, and Quality Control," Transfusion 1997:37.
13. Patton GA, Skowronski MG, "Implementation of a Blood Irradiation Program at a Community Cancer Center," Transfusion 2001:41.
14. Ness PM, Lipton KS, "Selective Transfusion Protocols: Errors and Accidents Waiting to Happen," Transfusion 2001:41:713-715.
15. Dwyre DM & Holland PV. "Transfusion-associated graft-versus-host disease," Vox Sang 2008:95(2):85-93.